Is Trident Lifeline overvalued or undervalued?

As of 5 September 2025, Trident Lifeline's valuation grade has moved from very expensive to expensive, indicating a shift in its perceived market value. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE Ratio of 20.13, an EV to EBITDA of 15.30, and a PEG Ratio of 0.24, which suggests that while growth expectations may be low, the current price does not reflect a favorable investment opportunity. In comparison with peers, Trident Lifeline's PE Ratio is significantly lower than that of Sun Pharma, which stands at 33.33, and Divi's Lab at 69.2, both categorized as very expensive. On the other hand, companies like Dr. Reddy's Labs and Cipla, which are rated attractive, have PE Ratios of 18.65 and 23.25, respectively. Additionally, Trident Lifeline has underperformed against the Sensex, with a 1-year return of -16.77% compared to the Sensex's -1.81%, reinforcing the notion that the stock may not be a compelling buy at its current valuation.